WSJ Pro VC Daily: Biotech Acquisitions Could Be Poised for Second-Half Rebound
WSJ Pro VC Daily: Biotech Acquisitions Could Be Poised for Second-Half Rebound
WSJ Pro VC Daily: Biotech Acquisitions Could Be Poised for Second-Half Reboundhttps://eyevensys.com/wp-content/themes/crocal/images/empty/thumbnail.jpg150150EyevensysEyevensyshttps://eyevensys.com/wp-content/themes/crocal/images/empty/thumbnail.jpg
Paris- and Cambridge, Mass.-based biotech company developing therapies for ophthalmic diseases raised $12 million in Series B+ funding, led by Korea Investment Partners.
